DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients

Sasaki,Hidefumi; Shitara,Masayuki; Yokota,Keisuke; Okuda,Katsuhiro; Hikosaka,Yu; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/ol.2012.684

DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients

Authors:
- Hidefumi Sasaki
- Masayuki Shitara
- Keisuke Yokota
- Katsuhiro Okuda
- Yu Hikosaka
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Published online on: April 18, 2012 https://doi.org/10.3892/ol.2012.684
Pages: 33-37

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Discoidin domain receptor 2, DDR2, is a tyrosine kinase receptor for fibrillar collagen that is involved in postnatal development, tissue repair and primary and metastatic cancer progression. Recently, mutations in the DDR2 kinase gene were identified in squamous cell lung cancer from large‑scale Sanger sequencing. The present study investigated the DDR2 gene mutations and mRNA expression in surgically treated non-small cell lung cancer (NSCLC) of squamous histology cases. The presence or absence of DDR2 mutations at the kinase and discoidin domain was analyzed by direct sequencing. In this cohort, DDR2 mutations were not observed in the 166 patients with lung cancer, although DDR2 polymorphisms were observed (H136H, n=14) at the discoidin domain. mRNA levels of DDR2 in lung tumor samples and the adjacent normal lung samples were simultaneously analyzed. DDR2 mRNA levels were significantly decreased in tumor samples compared with normal lung samples. However, the DDR2 mRNA levels were elevated in the DDR2 polymorphism cases.

View Figures

View References

1	Ginsberg RJ, Kris K and Armstrong G: Cancer of the lung. Principles and Practice of Oncology. 4th edition. Lippincott; Philadelphia: pp. 673–682. 1993
2	Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
3	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
4	Sasaki H, Endo K, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005. View Article : Google Scholar : PubMed/NCBI
5	Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
6	Fukuoka M, Wy YL, Thongprasert S, et al: Biomarker analyses and first overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar
7	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
8	Hammerman PS, Sos ML, Ramos AH, et al: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery. 1:78–89. 2011. View Article : Google Scholar : PubMed/NCBI
9	Vogel WF, Abdulhussein R and Ford CE: Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal. 18:1108–1116. 2006. View Article : Google Scholar : PubMed/NCBI
10	Ford CE, Lau SK, Zhu CQ, et al: Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer. 96:808–814. 2007. View Article : Google Scholar : PubMed/NCBI
11	Davies H, Hunter C, Smith R, et al: Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65:7591–7595. 2005.PubMed/NCBI
12	Johnson JD, Edman JC and Rutter WJ: A receptor tyrosine kinase found in breast carcinoma cell has an extracellular discoidin I-like domain. Proc Natl Acad Sci USA. 90:5677–5681. 1993. View Article : Google Scholar
13	Alves F, Vogel W, Mossie K, et al: Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. Oncogene. 10:609–618. 1995.
14	Barker KT, Martindale JE, Mitchell PJ, et al: Expression patterns of the novel receptor-like tyrosine kinase, DDR, in human breast tumors. Oncogene. 10:569–575. 1995.PubMed/NCBI
15	Nemoto T, Ohashi K, Akashi T, et al: Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology. 65:195–203. 1997. View Article : Google Scholar : PubMed/NCBI
16	Vogel W, Gish GD, Alves F, et al: The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell. 1:13–23. 1997. View Article : Google Scholar : PubMed/NCBI
17	Olaso E, Labrador JP, Wang L, et al: Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem. 277:3606–3613. 2002. View Article : Google Scholar
18	Olaso E, Ikeda K, Eng FJ, et al: DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest. 108:1369–1378. 2001. View Article : Google Scholar : PubMed/NCBI
19	Xu L, Peng H, Wu D, et al: Activation of the discoidin domain receptor 2 induces expression of matrix metalloproteinase 13 associated with osteoarthritis in mice. J Biol Chem. 280:548–555. 2005. View Article : Google Scholar : PubMed/NCBI
20	Badiola I, Villacé P, Basaldua I, et al: Downregulation of discoidin domain receptor 2 in A375 human melanoma cells reduces its experimental liver metastasis ability. Oncol Rep. 26:971–978. 2011.PubMed/NCBI
21	Day E, Waters B, Spiegel K, et al: Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 599:44–53. 2008. View Article : Google Scholar : PubMed/NCBI
22	Bantscheff M, Eberhard D, Abraham Y, et al: Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotech. 25:1035–1044. 2007. View Article : Google Scholar : PubMed/NCBI